Key takeaways: The FDA has approved the world’s first vaccine for Respiratory Syncytial Virus (RSV) for adults aged 60 and up, made by GSK. The single-dose shot was found to lower the risk of symptomatic illness by 83% and of severe illness by 94% in a late-stage clinical trial. The approval of the RSV vaccine is a major milestone in…